ALSO NOTED: University provides free HPV shots; Intercell reports successful mid-stage hep C study; Tattooing effective in deli

Vaccine Market

Sentry Logistic Solutions in Indianapolis has won a contract from the CDC to store the national strategic reserve supply of the influenza virus vaccine. Report

The University of Washington has begun to provide free HPV shots to students. Report

A new standard requiring that hospitalized children get a flu vaccination would help prevent a wide range of hospitalizations and complications from the flu, according to a team of researchers. Release

UNICEF and the World Health Organization are appealing for funds to provide mumps vaccine to Moldovans in the wake of a severe outbreak of the disease. Report

Vaccine maker Emergent BioSolutions spent about $1.3 million lobbying the U.S. government on a bill involving Project BioShield. Story

Vaccine Research

Austria's Intercell says that a mid-stage study of its hepatitis C vaccine--IC41--demonstrated an average reduction in viral load of 60 percent. Report

Martin Müller and his team at the Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany, have shown that tattooing is a more effective way of delivering DNA vaccines than intramuscular injection. Release

Shares of Bioniche Life Sciences took off after a U.S. agency said that its E. coli vaccine for cattle qualifies for conditional licensing. The vaccine prohibits animals from shedding E. coli in manure. Report

A research team headed by the international Ludwig Institute for Cancer Research has shown that a vaccine against a protein found in cancer cells produces an immune response that can be boosted and strengthened with additional vaccine shots. Release

Scientists at The Wistar Institute Vaccine Center have been experimenting with a herpes simplex protein called glycoprotein D to block a specific receptor molecule on antigen-presenting cells, or APCs. When they detect viral antigens, APCs signal the body's immune system to activate T cells to attack and destroy cells infected with the virus. At the same time, they also send inhibitory signals to prevent overreaction by the immune system. The approach is expected to balance the human immune response--making it strong enough to king a viral disease like AIDS but not so strong that it kills the host. Release

Two novel proteins studied by a University at Buffalo professor of microbiology and immunology appear to have the potential to enhance the production of antibodies against a multitude of infectious agents. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.